Greenbrook TMS Inc.
GTMS.TO
Toronto Stock Exchange0.97
CAD
-0.18
- -
Greenbrook TMS Inc.
GTMS.TO
(Toronto Stock Exchange)
Recent
price
0.97
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Greenbrook TMS Inc. (TSX: GTMS) operates as a leading provider of transcranial magnetic stimulation (TMS) therapy and esketamine treatments for major depressive disorder (MDD), treatment-resistant depression (TRD), obsessive-compulsive disorder (OCD), and related mental health conditions in the United States. The company delivers FDA-cleared NeuroStar TMS therapy, a non-invasive, non-medication treatment that uses electromagnetic pulses to target brain regions associated with mood regulation; FDA-approved SPRAVATO (esketamine) nasal spray treatment for TRD and MDD with acute suicidal ideation or actions; and related behavioral health services through over 95 company-operated centers nationwide, including locations in Florida, Pennsylvania, Illinois, New Jersey, Nevada, Wisconsin, Maryland, and other states. Greenbrook handles insurance verification, prior authorizations, claims processing, and patient care coordination, serving patients who have not responded to traditional antidepressants or talk therapy, with treatments covered by most major insurers, Medicare, and Medicaid in select locations. Founded in 2011 and headquartered in Toronto, Ontario, Canada, the company previously expanded through acquisitions such as Success TMS in July 2022, adding 47 centers and a US$75 million credit facility from Madryn Asset Management; Achieve TMS East and Central in 2021; and other regional providers to reach nearly 200 centers at peak. In July 2025, Neuronetics Inc. acquired Greenbrook in a US$45 million all-stock transaction valued at approximately $60 million, under a court-approved plan of arrangement, whereby Greenbrook shareholders received 0.01149 Neuronetics shares per share, resulting in 43% ownership of the combined entity operating as Neuronetics; Madryn converted its debt into Greenbrook shares prior to closing.